NewcelX Ltd. — Company profile
Healthcare · Biotechnology · Switzerland
Last price 2.55 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 14.73M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
Details
| Name | NewcelX Ltd. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 12 |
| Founded | 2008 |
| Ceo | Ronen Twito |
| Country | Switzerland |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | CH1442297896 |
| Cusip | H5835A109 |
| Cik | 0001783036 |
Key executives
| Name | Title |
|---|---|
| Ronen Twito CPA | Chief Executive Officer and Executive Chairman |
| Prof. Michel Revel M.D., Ph.D. | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board and Director |
| Omri Hagai | Chief Financial Officer |
| Alexander C. Zwyer M.B.A. | Chief Business Officer and Executive Director |
| Dr. Eric Konofal M.D., Ph.D. | Head of Doxa Program |
| Prof. Ariel Revel M.D. | Director of Medical Affairs |
Contact
| Address | Hohstrasse 1, Kloten, 8302, Switzerland |
| Phone | 41 44 512 21 50 |
| Website | https://newcelx.com |